LENSAR Q4 2021 revenue $11.2M (+35% YoY); full-year revenue up 31% to $34.2M; net loss narrows

LENSAR, Inc.

Q4 revenue $11.2M vs $8.3M YoY; full-year revenue $34.2M (+31% vs 2020).
Net loss $3.9M ($0.41 per share) vs $6.8M ($0.78) in Q4 2020; loss narrowed.
Procedure volume up 37% in Q4 and 35% for full year 2021.
ALLY Adaptive Cataract Treatment System 510(k) submitted and accepted for FDA substantive review.
Cash of $31.6M with only $0.7M used in Q4; commercial launch of ALLY expected in 2022 subject to FDA clearance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.